Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022)

Dianthus Therapeutics (DNTH) has 2 years of Preferred Stock Liabilities data on record, last reported at $118.0 million in Q4 2022.

  • For Q4 2022, Preferred Stock Liabilities changed N/A year-over-year to $118.0 million; the TTM value through Dec 2022 reached $118.0 million, changed N/A, while the annual FY2022 figure was $118.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $118.0 million in Q4 2022 per DNTH's latest filing, up from $92.4 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $118.0 million in Q4 2022 and bottomed at $118.0 million in Q4 2022.